Stock DNA
Pharmaceuticals & Biotechnology
JPY 6,825 Million (Micro Cap)
NA
0.00%
-1.08
-999,999.00%
2.52
Revenue and Profits:
Net Sales:
133 Million
(Quarterly Results - Dec 2025)
Net Profit:
-286 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
25.49%
0%
25.49%
6 Months
11.63%
0%
11.63%
1 Year
-31.91%
0%
-31.91%
2 Years
0%
0%
0.0%
3 Years
0%
0%
0.0%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%
PRISM BioLab Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
0
EBIT to Interest (avg)
0
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
0
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
Industry P/E
Price to Book Value
EV to EBIT
EV to EBITDA
EV to Capital Employed
EV to Sales
PEG Ratio
NA
Dividend Yield
ROCE (Latest)
ROE (Latest)
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bullish
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Annual Results Snapshot (Consolidated) - Sep'25
Sep'25
Sep'24
Change(%)
Net Sales
677.30
305.60
121.63%
Operating Profit (PBDIT) excl Other Income
-774.50
-782.40
1.01%
Interest
0.00
0.00
Exceptional Items
-83.00
-237.60
65.07%
Consolidate Net Profit
-833.70
-1,049.50
20.56%
Operating Profit Margin (Excl OI)
-1,143.40%
-2,560.00%
141.66%
USD in Million.
Net Sales
YoY Growth in year ended Sep 2025 is 121.63% vs 170.68% in Sep 2024
Consolidated Net Profit
YoY Growth in year ended Sep 2025 is 20.56% vs -99.18% in Sep 2024






